In 2024, the in vitro diagnostics market was estimated to be worth USD 80.02 billion. With a compound annual growth rate (CAGR) of 6.7% from 2025 to 2034, the market is expected to increase from USD 85.21 billion in 2025 to USD 152.62 billion.
Market Overview:
Tests that identify illnesses, infections, and other conditions outside of the body, usually in a laboratory setting, are known as in vitro diagnostics, or IVDs. “In vitro” is derived from the Latin phrase “in glass.” In contrast to IVDs, in vivo diagnostics include imaging tests like positron emission tomography, magnetic resonance imaging, and ultrasound scanning that are carried out directly on a patient. IVDs may consist of instruments, reagents, or other systems. They are employed in the diagnosis, treatment, and monitoring of medical conditions. Pregnancy tests, COVID-19 tests, HIV tests, and cancer diagnostics are a few types of IVD products.
𝐆𝐞𝐭 𝐄𝐱𝐜𝐥𝐮𝐬𝐢𝐯𝐞 𝐒𝐚𝐦𝐩𝐥𝐞 𝐏𝐚𝐠𝐞𝐬 𝐨𝐟 𝐓𝐡𝐢𝐬 𝐑𝐞𝐩𝐨𝐫𝐭:
Market Growth Promotors:
- The need for early and accurate disease detection is driving the strong growth of the IVD market.
- One major factor propelling the in vitro diagnostics market is the growing aging population, particularly in developed countries.
- Point-of-care testing’s incorporation into clinical practice promotes innovation. It increases diagnostic capabilities, propelling market expansion as global healthcare systems adopt these advanced tools more frequently in order to satisfy the rising demand for quicker and more accurate diagnostics.
Key Market Players:
The in vitro diagnostics market will continue to grow as a result of major market players making significant investments in R&D to broaden their product lines. Some of the major participants in the market are:
- Abbott
- Agilent Technologies, Inc.
- Becton, Dickinson and Company
- bioMérieux SA
- Bio-Rad Laboratories, Inc.
- Charles River Laboratories
- Danaher Corporation
- Hoffmann-La Roche Ltd.
- Qiagen
Segmental Overview:
The research report categorizes the market into various segments and sub-segments. The market is primarily segmented based on product and service outlook, technology, specimen, application, end user. The splitting of the market into various groups enables businesses to understand market preferences and trends better.
In Vitro Diagnostics Market, Product & Service Outlook (Revenue, USD Billion, 2020-2034)
- Reagents & Kits
- Instruments
- Data Management Software and Services
In Vitro Diagnostics Market, Technology Outlook (Revenue, USD Billion, 2020-2034)
- Immunoassays
- Clinical Chemistry
- Molecular Diagnostics
- Hematology
- Microbiology
- Coagulation & Hemostasis
- Urinalysis
- Chromatography & Mass Spectrometry
- Others
In Vitro Diagnostics Market, Application Outlook (Revenue, USD Billion, 2020-2034)
- Infectious Diseases
- Oncology
- Endocrinology
- Cardiology
- Blood Screening
- Genetic Testing
- Autoimmune Diseases
- Allergy Diagnostics
- Drug Monitoring & Testing
- Bone & Mineral Disorders
- Coagulation Testing
- Blood Group Testing
- Others
In Vitro Diagnostics Market, Specimen Outlook (Revenue, USD Billion, 2020-2034)
- Blood, Serum, and Plasma
- Saliva
- Urine
- Other
Future Scope
The In Vitro Diagnostics (IVD) market is poised for robust growth, driven by technological advancements, precision medicine initiatives, and a growing emphasis on early, personalized, and remote patient care. New testing platforms will leverage innovations in molecular diagnostics, next-generation sequencing, and AI-driven data interpretation, enabling faster, more accurate diagnoses from smaller sample volumes. As value-based care models gain traction, IVD solutions integrated into digital health ecosystems will facilitate proactive health monitoring and more efficient disease management. Emerging economies, increased testing in decentralized settings, and a focus on preventive screening will further broaden IVD adoption, ensuring a dynamic, innovation-rich future.
Recent Developments in the In Vitro Diagnostics (IVD) Market
January 2024: ELITechGroup’s CE-IVDR Certified GI Bacterial PLUS ELITe MGB® Kit
ELITechGroup launched the GI Bacterial PLUS ELITe MGB® Kit, a CE-IVDR certified multiplex real-time PCR assay for detecting gastrointestinal bacterial infections. Validated with the ELITe InGenius® and ELITe BeGenius® systems, this kit enables precise diagnostics from human stool specimens. The company plans to expand its IVD portfolio with additional kits targeting parasitic and viral pathogens, including the GI Parasitic PLUS ELITe MGB® Kit and the GI Norovirus PLUS ELITe MGB® Kit.
November 2023: Roche’s LightCycler® PRO System
Roche introduced the LightCycler® PRO System, an advanced quantitative PCR (qPCR) platform designed to enhance clinical diagnostics and research. Building upon established LightCycler® technology, this system offers improved performance and usability, bridging translational research and in vitro diagnostics. It supports personalized healthcare and outbreak readiness by providing flexibility for various applications.
September 2023: NeoDx Biotech Labs’ HLA-B27 Real-Time PCR Kit
NeoDx Biotech Labs launched a real-time PCR-based in vitro diagnostic kit for detecting the HLA-B27 allele. This advancement facilitates the early identification of autoimmune disorders such as Ankylosing Spondylitis, enabling timely intervention and improved patient management.
These developments underscore the IVD industry’s commitment to advancing diagnostic technologies, enhancing disease detection, and supporting personalized medicine.